Shots: The US FDA’s ODAC has voted 12-0 in favor of the demonstrated benefit of belantamab mafodotin monothx. outweighing the risks for patients with r/r MM prior treated with at […]readmore
Tags : Belantamab Mafodotin
Shots: The MAA is based on DREAMM-2 P-II study (DRiving Excellence in Approaches to Multiple Myeloma) study which involves assessing of Belantamab Mafodotin in heavily pre-treated patients with MM who […]readmore
Shots: The PR status is based on P-II DREAMM-2 study assessing two doses of Belantamab Mafodotin (GSK2857916) in patients with r/r MM who are refractory to a proteasome inhibitor and […]readmore